Able Labs To Withdraw Seven Approved ANDAs, Recall All Products
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is concerned about the reliability of data underlying the applications and says further ANDA withdrawals could be forthcoming. Able also is suspending manufacturing and distribution operations and recalling all of its products.
You may also be interested in...
FDA Rejects Able Labs’ Plan To Return Products To Market
Able plans to sell its business and assets rather than pursue full resubmission of its ANDAs.
FDA Rejects Able Labs’ Plan To Return Products To Market
Able plans to sell its business and assets rather than pursue full resubmission of its ANDAs.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: